- cafead Jul 23, 2024 at 06:52: PM
via Jaguar Health said an initial analysis of anti-diarrhoeal drug Mytesi (crofelemer) in cancer patients showed the Phase III trial did not meet its primary endpoint.
Shares in the Nasdaq-listed company opened 66% lower compared to a pre-announcement market close. Jaguar has a market cap of $12m.
article source
Shares in the Nasdaq-listed company opened 66% lower compared to a pre-announcement market close. Jaguar has a market cap of $12m.
article source